Trial | % BCS Neoadjuvant Therapy | % BCS Surgery First |
Royal Marsden [19] | 89% | 78% |
Institut Curie [20] | 82% | 77% |
NSABP B-18 [21] | 67% | 60% |
EORTC [22] | 37% | 21% |